Treating hyperphosphatemia involves three main strategies: reducing phosphorus intake through diet, binding phosphorus in the gut with medications so it passes through without being absorbed, and removing it through dialysis when kidney function is severely impaired. Most people with this condition have chronic kidney disease, and treatment typically combines all three approaches since no single one is sufficient on its own.
Why Phosphorus Builds Up
Healthy kidneys filter excess phosphorus out of your blood. When kidney function declines, phosphorus accumulates because the kidneys can no longer keep up. Over time, elevated phosphorus pulls calcium from your bones, weakens your skeleton, and deposits calcium-phosphorus crystals in your blood vessels, heart valves, and soft tissues. This vascular calcification is a major reason hyperphosphatemia raises cardiovascular risk in people with kidney disease.
Less commonly, hyperphosphatemia results from other conditions. Vitamin D toxicity can raise phosphorus levels by increasing intestinal absorption. Hypoparathyroidism reduces the hormone signal that tells kidneys to excrete phosphorus. In these cases, treatment focuses on correcting the underlying problem rather than the phosphorus-centered approach used in kidney disease.
Dietary Changes That Make a Real Difference
Not all phosphorus in food behaves the same way in your body. The phosphorus naturally found in animal proteins (meat, poultry, fish, dairy) is absorbed at a rate of 40% to 70%. Plant-based phosphorus from beans, nuts, and grains falls on the lower end of that range because much of it is bound in a form your body can’t easily break down.
The real problem is phosphate additives in processed foods. These inorganic phosphates are absorbed at rates above 90%, making them far more impactful than the same amount of phosphorus from whole foods. They show up in fast food, processed meats, canned goods, bottled beverages (especially colas, which contain phosphoric acid), and frozen meals. On ingredient labels, look for terms like dicalcium phosphate, disodium phosphate, monosodium phosphate, sodium hexametaphosphate, trisodium phosphate, sodium tripolyphosphate, and tetrasodium pyrophosphate.
The practical takeaway: switching from processed to whole foods can meaningfully lower your phosphorus load even before you start restricting specific food groups. When you do need to limit high-phosphorus whole foods, plant sources are generally a better trade-off than animal sources because you absorb less of the phosphorus they contain. Choosing plant proteins over dairy or meat when possible lets you maintain adequate protein intake while keeping absorbed phosphorus lower.
Phosphate Binders: The Core Medication
Phosphate binders are pills you take with meals. They work by chemically grabbing phosphorus in your digestive tract before it reaches your bloodstream, so it leaves your body in your stool instead. The timing matters: binders only work if they’re in your gut at the same time as the food, so taking them between meals does very little.
The major challenge with binders is pill burden. Dialysis patients take an average of 6 pills per day just for phosphorus control, with some prescribed 12 or more. In a large international study, 45% of patients reported skipping their binders at least once in the past month, and the more pills prescribed, the more likely patients were to skip doses. This is one of the most common reasons hyperphosphatemia remains poorly controlled despite available treatments.
Calcium-Based Binders
Calcium carbonate and calcium acetate are the oldest and least expensive options. They work well at lowering phosphorus, but the calcium they deliver creates its own problem. Current guidelines recommend that total elemental calcium intake from binders plus diet should not exceed 2,500 mg per day, with the binder portion ideally staying under 1,500 mg per day for dialysis patients. Exceeding this raises the risk of high blood calcium levels, which can accelerate the very vascular calcification you’re trying to prevent. For this reason, calcium-based binders have become less favored as first-line therapy, particularly in patients who already have signs of calcification or elevated calcium levels.
Non-Calcium Binders
Sevelamer carbonate and lanthanum carbonate avoid the calcium-loading problem entirely. In a head-to-head clinical study, sevelamer (starting at 800 mg three times daily with meals) reduced serum phosphorus by 38% over six months, while lanthanum (starting at 500 mg three times daily) achieved a 54% reduction over the same period. Both brought patients from dangerously high levels down into or near the target range.
Sevelamer has the added benefit of modestly lowering LDL cholesterol. Lanthanum tablets are chewable, which some patients find easier than swallowing additional pills. The main downside of both is cost, as they are significantly more expensive than calcium-based options.
Iron-Based Binders
Sucroferric oxyhydroxide is a newer option that binds phosphorus using iron rather than calcium. It requires fewer pills per day (typically 2 to 6 tablets) compared to sevelamer (which can require 3 to 18 tablets daily for equivalent control), making it appealing for patients struggling with pill burden. Over 24 weeks, patients on sucroferric oxyhydroxide also saw a modest improvement in iron stores: transferrin saturation increased by about 4.6% and hemoglobin rose slightly, likely because a small amount of iron is absorbed. For dialysis patients who are often iron-deficient, this secondary effect can be a bonus, though it’s not large enough to replace iron supplementation.
A Newer Approach: Blocking Phosphorus Absorption Directly
Tenapanor works through a completely different mechanism than traditional binders. Instead of grabbing phosphorus in the gut, it tightens the junctions between cells lining the intestinal wall. Most dietary phosphorus actually slips between intestinal cells through these gaps (called paracellular transport) rather than being actively pumped through the cells themselves. By reducing the permeability of these gaps, tenapanor cuts passive phosphorus absorption at its source. It also decreases the activity of the main active phosphorus transporter in the intestine, adding a second layer of reduction.
Because it works on a different pathway, tenapanor can be used alongside phosphate binders for patients whose levels remain stubbornly high. In healthy volunteers, a dose of 15 mg twice daily for four days increased the amount of phosphorus exiting in stool while decreasing the amount appearing in urine, confirming that less phosphorus was making it into the bloodstream. The most common side effect is diarrhea, which is related to its primary action of reducing sodium absorption in the gut.
The Role of Dialysis
Standard hemodialysis, performed three times per week for about four hours per session, removes some phosphorus from the blood but rarely enough on its own. Phosphorus clearance during dialysis is limited because phosphorus moves slowly from tissues into the bloodstream, so even long sessions hit a ceiling. This is why diet and binders remain essential even for patients on dialysis.
More frequent or longer dialysis sessions, such as daily or overnight treatments, generally improve phosphorus removal. Some patients on intensive dialysis schedules are able to reduce or even stop their phosphate binders, though this depends heavily on dietary intake and residual kidney function.
When the Cause Isn’t Kidney Disease
Hyperphosphatemia caused by vitamin D toxicity resolves by stopping vitamin D and calcium supplements, correcting dehydration with fluids to increase the kidneys’ ability to clear both calcium and phosphorus, and avoiding prolonged bed rest (which releases minerals from bone). Severe cases with dangerously high calcium levels may require hospital-based treatment to bring calcium down quickly.
In hypoparathyroidism, the underlying hormone deficiency means the kidneys retain too much phosphorus. Treatment centers on replacing parathyroid hormone or using active vitamin D carefully to restore the balance between calcium and phosphorus, with dietary phosphorus restriction playing a supporting role. The approach is quite different from CKD-related hyperphosphatemia because kidney function itself is normal.
Making Treatment Stick
The biggest obstacle in managing hyperphosphatemia isn’t the lack of effective treatments. It’s the difficulty of following them consistently. Taking 6 or more pills with every meal, reading every food label for hidden additives, and restricting foods you enjoy is genuinely hard to sustain long-term. Nearly half of dialysis patients report skipping binders regularly, and those prescribed more pills skip more often.
A few strategies can help. Simplifying the binder regimen by using options with a lower pill count (like sucroferric oxyhydroxide) may improve consistency. Focusing dietary effort on eliminating processed foods with phosphate additives, rather than obsessively restricting every natural source of phosphorus, targets the highest-impact change first. And working with a renal dietitian to find practical substitutions for your actual eating habits, rather than following a generic restricted list, tends to produce more sustainable results.